|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goff BA, Mandel L, Muntz HG and Melancon
CH: Ovarian carcinoma diagnosis. Cancer. 89:2068–2075. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bookman MA, Brady MF, McGuire WP, Harper
PG, Alberts DS, Friedlander M, Colombo N, Fowler JM, Argenta PA, De
Geest K, et al: Evaluation of new platinum-based treatment regimens
in advanced-stage ovarian cancer: A Phase III Trial of the
Gynecologic Cancer Intergroup. J Clin Oncol. 27:1419–1425. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Khalil AM, Guttman M, Huarte M, Garber M,
Raj A, Morales Rivea D, Thomas K, Presser A, Bernstein BE, van
Oudenaarden A, et al: Many human large intergenic noncoding RNAs
associate with chromatin-modifying complexes and affect gene
expression. Proc Natl Acad Sci USA. 106:11667–11672. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ulitsky I and Bartel DP: lincRNAs:
Genomics, evolution, and mechanisms. Cell. 154:26–46. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Baldinu P, Cossu A, Manca A, Satta MP,
Sini MC, Rozzo C, Dessole S, Cherchi P, Gianfrancesco F, Pintus A,
et al: Identification of a novel candidate gene, CASC2, in a region
of common allelic loss at chromosome 10q26 in human endometrial
cancer. Hum Mutat. 23:318–326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Baldinu P, Cossu A, Manca A, Satta MP,
Sini MC, Palomba G, Dessole S, Cherchi P, Mara L, Tanda F and
Palmieri G: CASC2a gene is down-regulated in endometrial cancer.
Anticancer Res. 27:235–243. 2007.PubMed/NCBI
|
|
8
|
He X, Liu Z, Su J, Yang J, Yin D, Han L,
De W and Guo R: Low expression of long noncoding RNA CASC2
indicates a poor prognosis and regulates cell proliferation in
non-small cell lung cancer. Tumour Biol. 37:9503–9510. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gan Y, Han N, He X, Yu J, Zhang M, Zhou Y,
Liang H, Deng J, Zheng Y, Ge W, et al: Long non-coding RNA CASC2
regulates cell biological behaviour through the MAPK signalling
pathway in hepatocellular carcinoma. Tumor Biol.
39:10104283177062292017. View Article : Google Scholar
|
|
10
|
Wang R, Li Y, Zhu G, Tian B, Zeng W, Yang
Y and Li Z: Long noncoding RNA CASC2 predicts the prognosis of
glioma patients and functions as a suppressor for gliomas by
suppressing Wnt/β-catenin signaling pathway. Neuropsychiatr Dis
Treat. 13:1805–1813. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou J, Huang H, Tong S and Huo R:
Overexpression of long non-coding RNA cancer susceptibility 2
inhibits cell invasion and angiogenesis in gastric cancer. Mol Med
Rep. 16:5235–5240. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cao Y, Xu R, Xu X, Zhou Y, Cui L and He X:
Downregulation of lncRNA CASC2 by microRNA-21 increases the
proliferation and migration of renal cell carcinoma cells. Mol Med
Rep. 14:1019–1025. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Y, Liang S, Zhou Y, Li S, Li Y and Liao
W: HNF1A/CASC2 regulates pancreatic cancer cell proliferation
through PTEN/Akt signaling. J Cell Biochem. 2017.(Epub ahead of
print). View Article : Google Scholar
|
|
14
|
Yang X, Wang J, Li WP, Jin ZJ and Liu XJ:
Desmocollin 3 mediates follicle stimulating hormone-induced ovarian
epithelial cancer cell proliferation by activating the EGFR/Akt
signaling pathway. Int J Clin Exp Patho. 8:6716–6723. 2015.
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Prat J: Staging classification for cancer
of the ovary, fallopian tube, and peritoneum. International journal
of gynaecology and obstetrics: The official organ of the
International Federation of Gynaecology and Obstetrics. 124:1–5.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bhan A, Soleimani M and Mandal SS: Long
Noncoding RNA and Cancer: A New Paradigm. Cancer Res. 77:3965–3981.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jarroux J, Morillon A and Pinskaya M:
History, discovery, and classification of lncRNAs. Adv Exp Med
Biol. 1008:1–46. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen L, Liu W, Cui J, Li J and Li C:
Analysis of long non-coding RNA expression profiles in ovarian
cancer. Oncol Lett. 14:1526–1530. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou M, Sun Y, Sun Y, Xu W, Zhang Z, Zhao
H, Zhong Z and Sun J: Comprehensive analysis of lncRNA expression
profiles reveals a novel lncRNA signature to discriminate
nonequivalent outcomes in patients with ovarian cancer. Oncotarget.
7:32433–32448. 2016.PubMed/NCBI
|
|
21
|
Wang LL, Sun KX, Wu DD, Xiu YL, Chen X,
Chen S, Zong ZH, Sang XB, Liu Y and Zhao Y: DLEU1 contributes to
ovarian carcinoma tumourigenesis and development by interacting
with miR-490-3p and altering CDK1 expression. J Cell Mol Med.
21:3055–3065. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Medrzycki M, Zhang Y, Zhang W, Cao K, Pan
C, Lailler N, McDonald JF, Bouhassira EE and Fan Y: Histone h1.3
suppresses h19 noncoding RNA expression and cell growth of ovarian
cancer cells. Cancer Res. 74:6463–6473. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong L and Hui L: HOTAIR promotes
proliferation, migration, and invasion of ovarian cancer SKOV3
cells through regulating PIK3R3. Med Sci Monit. 22:325–331. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Teschendorff AE, Lee SH, Jones A, Fiegl H,
Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, et al:
HOTAIR and its surrogate DNA methylation signature indicate
carboplatin resistance in ovarian cancer. Genome Med. 7:1082015.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhang Z, Cheng J, Wu Y, Qiu J, Sun Y and
Tong X: LncRNA HOTAIR controls the expression of Rab22a by sponging
miR-373 in ovarian cancer. Mol Med Rep. 14:2465–2472. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ozes AR, Miller DF, Ozes ON, Fang F, Liu
Y, Matei D, Huang T and Nephew KP: NF-κB-HOTAIR axis links DNA
damage response, chemoresistance and cellular senescence in ovarian
cancer. Oncogene. 35:5350–5361. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chai Y, Liu J, Zhang Z and Liu L:
HuR-regulated lncRNA NEAT1 stability in tumorigenesis and
progression of ovarian cancer. Cancer Med. 5:1588–1598. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
An J, Lv W and Zhang Y: LncRNA NEAT1
contributes to paclitaxel resistance of ovarian cancer cells by
regulating ZEB1 expression via miR-194. Onco Targets Ther.
10:5377–5390. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou Y, Xu X, Lv H, Wen Q, Li J, Tan L, Li
J and Sheng X: The long noncoding RNA MALAT-1 is highly expressed
in ovarian cancer and induces cell growth and migration. PLoS One.
11:e01552502016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mitra R, Chen X, Greenawalt EJ, Maulik U,
Jiang W, Zhao Z and Eischen CM: Decoding critical long non-coding
RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat
Commun. 8:16042017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ren C, Li X, Wang T, Wang G, Zhao C, Liang
T, Zhu Y, Li M, Yang C, Zhao Y and Zhang GM: Functions and
mechanisms of long noncoding RNAs in ovarian cancer. Int J Gynecol
Cancer. 25:566–569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheng Z, Guo J, Chen L, Luo N, Yang W and
Qu X: A long noncoding RNA AB073614 promotes tumorigenesis and
predicts poor prognosis in ovarian cancer. Oncotarget.
6:25381–25389. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huang S, Qing C, Huang Z and Zhu Y: The
long non-coding RNA CCAT2 is up-regulated in ovarian cancer and
associated with poor prognosis. Diagn Pathol. 11:492016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yan C, Jiang Y, Wan Y, Zhang L, Liu J,
Zhou S and Cheng W: Long noncoding RNA NBAT-1 suppresses
tumorigenesis and predicts favorable prognosis in ovarian cancer.
Onco Targets Ther. 10:1993–2002. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Palmieri G, Paliogiannis P, Sini MC, Manca
A, Palomba G, Doneddu V, Tanda F, Pascale MR and Cossu A: Long
non-coding RNA CASC2 in human cancer. Crit Rev Oncol Hematol.
111:31–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ba Z, Gu L, Hao S, Wang X, Cheng Z and Nie
G: Downregulation of lncRNA CASC2 facilitates osteosarcoma growth
and invasion through miR-181a. Cell Prolif. 51:2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zeng F, Le YG, Fan JC and Xin L: LncRNA
CASC2 inhibited the viability and induced the apoptosis of
hepatocellular carcinoma cells through regulating miR-24-3p. J Cell
Biochem. 119:6391–6397. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liao Y, Shen L, Zhao H, Liu Q, Fu J, Guo
Y, Peng R and Cheng L: LncRNA CASC2 interacts with miR-181a to
modulate glioma growth and resistance to TMZ through PTEN pathway.
J Cell Biochem. 118:1889–1899. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jiang C, Shen F, Du J, Fang X, Li X, Su J,
Wang X, Huang X and Liu Z: Upregulation of CASC2 sensitized glioma
to temozolomide cytotoxicity through autophagy inhibition by
sponging miR-193a-5p and regulating mTOR expression. Biomed
Pharmacother. 97:844–850. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu C, Sun Y, She X, Tu C, Cheng X, Wang
L, Yu Z, Li P, Liu Q, Yang H, et al: CASC2c as an unfavorable
prognosis factor interacts with miR-101 to mediate astrocytoma
tumorigenesis. Cell Death Dis. 8:e26392017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang W, He W, Gao J, Wang Y, Zang W, Dong
Z and Zhao G: Retraction notice to the long noncoding RNA CASC2
inhibits tumorigenesis through modulating the expression of PTEN by
targeting miR-18a-5p in esophageal carcinoma. Exp Cell Res.
361:30–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang
C, Dou C, Xu M, Liu Q and Tu K: Long non-coding RNA CASC2
suppresses epithelial-mesenchymal transition of hepatocellular
carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer.
16:1232017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wang P, Liu YH, Yao YL, Li Z, Li ZQ, Ma J
and Xue YX: Long non-coding RNA CASC2 suppresses malignancy in
human gliomas by miR-21. Cell Signal. 27:275–282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Feng Y, Zou W, Hu C, Li G, Zhou S, He Y,
Ma F, Deng C and Sun L: Modulation of CASC2/miR-21/PTEN pathway
sensitizes cervical cancer to cisplatin. Arch Biochem Biophys.
623–624:20–30. 2017. View Article : Google Scholar
|
|
45
|
Pei Z, Du X, Song Y, Fan L, Li F, Gao Y,
Wu R, Chen Y, Li W, Zhou H, et al: Down-regulation of lncRNA CASC2
promotes cell proliferation and metastasis of bladder cancer by
activation of the Wnt/beta-catenin signaling pathway. Oncotarget.
8:18145–18153. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Xiong X, Zhu H and Chen X: Low expression
of long noncoding RNA CASC2 indicates a poor prognosis and promotes
tumorigenesis in thyroid carcinoma. Biomed Pharmacother.
93:391–397. 2017. View Article : Google Scholar : PubMed/NCBI
|
